文献速递慢性肾脏病水电解质与酸碱

衰弱、肾功能与多重用药:动脉粥样硬化风险社区(ARIC)研究

Frailty, Kidney Function, and Polypharmacy: The Atherosclerosis Risk in Communities (ARIC) Study.
PubMed 文献 · Am J Kidney Dis · 2016-11-22

在ARIC研究第5次随访(2011-2013年)的4987名社区居住老年人中,341人(7%)被判定为衰弱;衰弱者中基于血清肌酐的估算肾小球滤过率(eGFRcr)和基于血清胱抑素C的估算肾小球滤过率(eGFRcys)低于60mL/min/1.73m2的比例分别为45%和77%,且衰弱与eGFRcys及尿白蛋白-肌酐比值关联更强。作者认为,鉴于衰弱者用药负担重且慢性肾脏病分类存在不确定性,或需用替代生物标志物确认肾功能以确保谨慎处方。

要点

  • 衰弱者中eGFRcys<60mL/min/1.73m2的比例为77%,高于eGFRcr的45%。
  • eGFRcr为60至<75mL/min/1.73m2的衰弱者常被eGFRcys重分类至更低类别。
  • 衰弱者中超多重用药(≥10类药品)比例为54%,非衰弱者为38%。

核心结论

  • 衰弱个体中肾功能减退患病率高,且用eGFRcys与eGFRcr分类肾功能减退时存在较大差异。
  • 鉴于用药负担重和慢性肾脏病分类的不确定性,作者认为或需用替代生物标志物确认肾功能,以确保在这一脆弱人群中谨慎处方。

研究设计与样本

  • 观察性研究,纳入参与ARIC研究第5次随访(2011-2013年)且数据完整的4987名社区居住老年男性和女性。

主要发现

  • 341人(7%)被判定为衰弱,1475人(30%)eGFRcr<60mL/min/1.73m2,2480人(50%)eGFRcys<60mL/min/1.73m2,1006人(20%)有白蛋白尿且白蛋白排泄≥30mg/g。
  • 衰弱参与者中eGFRcr和eGFRcys<60mL/min/1.73m2的患病率分别为45%和77%。
  • 校正协变量后,衰弱与eGFRcr呈中度关联,与eGFRcys及白蛋白-肌酐比值呈强关联。
  • eGFRcr为60至<75mL/min/1.73m2的衰弱个体常被eGFRcys重分类至更低eGFR类别:49%至45-<60、32%至30-<45、3%至<30mL/min/1.73m2。
  • 超多重用药(服用≥10类药品)在衰弱个体中更常见(54% vs 非衰弱者38%),包括需肾脏清除的药物类别(如地高辛)以及与跌倒及后续并发症相关的类别(如催眠/镇静药和抗凝药)。

局限性

  • 横断面研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Frail individuals are at increased risk for poor outcomes, including adverse drug events. Kidney function is often compromised in frailty and is a key consideration in medication choice and dosing; however, creatinine-based measures of kidney function may be biased in frail individuals. STUDY DESIGN: Observational study. SETTING & PARTICIPANTS: 4,987 community-dwelling older men and women with complete data who participated in visit 5 of the Atherosclerosis Risk in Communities (ARIC) Study (2011-2013). PREDICTORS: Kidney measures included glomerular filtration rate (GFR) estimated using serum creatinine (eGFRcr) and serum cystatin C level (eGFRcys) and urine albumin-creatinine ratio. OUTCOME: Frailty, defined using established criteria of 3 or more frailty characteristics (weight loss, slowness, exhaustion, weakness, and low physical activity). RESULTS: 341 (7%) participants were classified as frail, 1,475 (30%) had eGFRcr<60mL/min/1.73m2, 2,480 (50%) had eGFRcys<60mL/min/1.73m2, and 1,006 (20%) had albuminuria with albumin excretion ≥ 30mg/g. Among frail participants, prevalences of eGFRcr and eGFRcys<60mL/min/1.73m2 were 45% and 77%, respectively. Adjusted for covariates, frailty showed a moderate association with eGFRcr and a strong association with eGFRcys and albumin-creatinine ratio. Frail individuals with eGFRcr of 60 to <75mL/min/1.73m2 were frequently reclassified to lower eGFR categories using eGFRcys (49% to 45-<60, 32% to 30-<45, and 3% to <30mL/min/1.73m2). Hyperpolypharmacy (taking ≥10 classes of medications) was more common in frail individuals (54% vs 38% of nonfrail), including classes requiring kidney clearance (eg, digoxin) and associated with falls and subsequent complications (eg, hypnotic/sedatives and anticoagulants). LIMITATIONS: Cross-sectional study design. CONCLUSIONS: Frail individuals had a high prevalence of reduced kidney function, with large discrepancies when reduced kidney function was classified by eGFRcys versus eGFRcr. Given the substantial medication burden and uncertainty in chronic kidney disease classification, confirmation of kidney function with alternative biomarkers may be warranted to ensure careful prescribing practices in this vulnerable population.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Ballew SH, Chen Y, Daya NR, et al. Frailty, Kidney Function, and Polypharmacy: The Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis. 2016. PMID: 27884475. doi:10.1053/j.ajkd.2016.08.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。